Avid Bioservices Inc (CDMO)

[biopharm]

KOL : Scott Antonia ... looking forward to what these guys have to say over the next 60 days.

http://www.peregrineinc.com/about-us/medical-and-scientific-advisors.html

Scott Antonia:

Scott Antonia, M.D., Ph.D., joined the Moffitt Cancer Center in 1994, determined to find better ways to treat the patients and fight the diseases that he sees every day.
That hasn’t changed almost 20 years later.

Advances have been made, but what we have now isn’t good enough. We have to do better.

Antonia is both the chairman of the Thoracic Oncology Department and co-leader of the Immunology Program at Moffitt, now in a leadership role that has expanded his reach at one of the nation’s leading cancer centers.

At Moffitt, he has developed a translational research program that has advanced immunotherapeutic strategies for the treatment of various cancers, including mesothelioma.
Better Therapies & Collaboration

He has focused on both immunotherapy and immunobiology, working extensively at gene modification to create tumor cell vaccines at both clinical and pre-clinical stages.

His strategy for developing better therapies revolves around three themes:

Develop gene-modified, tumor-cell vaccines that can produce anti-tumor immune responses.
Develop dendritic-cell-based vaccines.
Develop strategies designed to thwart the immunosuppressive mechanisms used by tumors to evade rejection.

Antonio also has worked on developing better collaboration between clinical research scientists and basic research scientists in hopes of accelerating novel therapeutic approaches to the trials.

Our principle motivation is to develop new therapies for unresectable (inoperable) tumors. Cancer treatments in general look more promising now than ever before, but we can’t stop now.

Antonia also is the leader of Moffitt’s newly created Mesothelioma Research and Treatment Center, joining surgeon Jacques Fontaine, M.D., oncologist Tawee Tanvetyanon, M.D. and radiologist Craig Stevens, M.D., PhD., in a collaborative effort.

Antonia is a professor of oncology at the nearby University of South Florida College of Medicine. He has done numerous novel studies that are highly acclaimed and has received patents on two technological advances that he developed.

Antonio received his medical degree and doctorate in immunology from the University of Connecticut Health Center. He was at Yale-New Haven Hospital for his residency, and both his medical oncology and immunobiology fellowships.

The National Cancer Institute awarded him a K24 grant to support his clinical research, and he was the principal investigator for a prestigious Specialized Programs of Research Excellence (SPORE) grant given to the Thoracic Oncology Department at Moffitt.

Antonia is the medical director of the Tumor Vaccine Production Facility at Moffitt, along with serving as the chairman of the Scientific Review Committee. He was Moffitt’s Physician of the Year in 2005.

http://www.asbestos.com/treatment/doctors/scott-antonia.php